Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 5/20 | 0.46 |
| ▸ | RARB | P10826 | 2/20 | 0.46 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503531 | 0.88 | PKM (0.56) | CTNNB1TP53TSHRRARGRARB | |
| SCHEMBL5356041 | 0.87 | MAPT (0.54) | KDM4ECTNNB1 | |
| SCHEMBL5390728 | 0.86 | KDM4E (0.67) | KDM4ETP53TSHR | |
| SCHEMBL2868546 | 0.84 | KMT2A (0.61) | TP53PLA2G4BPKM | |
| SCHEMBL7331781 | 0.84 | KDM4E (0.63) | KDM4ETP53TSHRRARBPLA2G4B | |
| SCHEMBL3947599 | 0.84 | RARB (0.62) | CTNNB1TP53TSHRRARGRARB | |
| SCHEMBL465181 | 0.80 | KDM4E (0.65) | KDM4ETP53TSHRRARBPLA2G4B | |
| SCHEMBL465148 | 0.80 | KDM4E (0.65) | KDM4ETP53TSHRRARBPLA2G4B | |
| SCHEMBL30726463 | 0.80 | KDM4E (0.65) | KDM4ETP53TSHRRARBPLA2G4B | |
| SCHEMBL25288063 | 0.79 | TSHR (0.55) | KDM4ETSHRRARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297342-A1 | MODULATORS OF CARNITINE OCTANOYLTRANSFERASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | Galderma Research & Development (FR) | 2011-03-23 | — | — | EP | disclosed |
| EP-2283157-A1 | GOS2 MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | Galderma Research & Development (FR) | 2011-02-16 | — | — | EP | disclosed |
| EP-2277043-A2 | SCREENING FOR MODULATORS OF CYP2B15 AND/OR GPD1 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | Galderma Research & Development (FR) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009135912-A1 | PCTP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135908-A1 | MODULATORS OF ISOVALERYL-COENZYME A DEHYDROGENASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPER SEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135915-A1 | MODULATORS OF MONOGLYCERIDE LIPASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135909-A1 | GOS2 MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135917-A2 | SCREENING FOR MODULATORS OF CYP2B15 AND/OR GPD1 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135907-A1 | ADFP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135913-A1 | MODULATORS OF CARNITINE OCTANOYLTRANSFERASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-11-12 | — | — | WO | disclosed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1572629-A1 | COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-14 | — | — | EP | disclosed |
| EP-1567509-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-08-31 | — | — | EP | disclosed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | disclosed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | disclosed |
| EP-1458697-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | Galderma Research & Development, S.N.C. (FR) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004052840-A1 | COMPOUNDS WHICH MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| WO-2003055867-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | KDM4E 3878/4885CTNNB1 2947/4885TP53 300/4885 |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | KDM4E 3745/4885CTNNB1 3921/4885TP53 384/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | KDM4E 3964/4885CTNNB1 3844/4885TP53 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.